StocksMedium•13 October 2026•
1 min read
Roche Strikes $1.16B Obesity Drug Deal with Rona Therapeutics
Key Facts
1Roche signed a licensing agreement with Chinese firm Rona Therapeutics to develop obesity treatments.
2The total potential value of the deal is approximately $1.16 billion, including upfront payments and milestones.
Roche signed a licensing agreement with Chinese firm Rona Therapeutics to develop obesity treatments. Reuters reported that the total potential value of the deal is approximately $1.16 billion, which includes upfront payments and various development milestones.
The agreement is part of Roche's strategy to compete in the high-growth weight-loss medication sector. Regarding market performance, RHHVF closed at $430.32 on October 12, 2026, after trading between a session high of $433.39 and a low of $429.36.